Browse News
Filter News
Found 16 articles
-
Biond Biologics Announces Presentation of BND-35, a Novel Anti-ILT3 Antibody for Remodeling the Tumor Microenvironment, at the American Association for Cancer Research (AACR) 2024 Annual Meeting
3/26/2024
Biond Biologics Ltd. is excited to announce that our BND-35 program has been selected for presentation at the esteemed American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 5 - 10, 2024, in San Diego Convention Center, San Diego, CA, USA.
-
The past decade has seen an immuno-oncology revolution, but there is still work to be done. BioSpace looks at innovative research from Nectin Therapeutics, Compugen and Biond Biologics.
-
Experimental Test Promises to Predict Side-Effects and Cancer's Return in Patients Treated with Immunotherapy
9/15/2022
A single research test has the potential to predict which patients treated with immunotherapies – which harness the immune system to attack cancer cells – are likely to have their cancer recur or have severe side effects, a new study found.
-
Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial
5/23/2022
First patients dosed in study sub-part evaluating BND-22 in combination with pembrolizumab or with cetuximab.
-
Biond Biologics to Present at the Raymond James LILRB/ILT Symposium
4/20/2022
Biond Biologics Ltd. today announced that Tehila Ben Moshe will be presenting therapeutics targeting ILTs (also known as LILRBs) at the LILRB/ILT Virtual Symposium titled: "Deep Dive into "Myeloid Checkpoint" Therapeutics in Cancer", hosted by Raymond James on April 26, 2022.
-
Biond Biologics Announces Oral Presentation for BND-67, an Inhibitor of CD28 Shedding, a Potential Novel Resistance Mechanism to Anti PD-1 Therapy, at the American Association for Cancer Research (AACR) 2022 Annual Meeting
3/21/2022
Biond Biologics Ltd., announced today that the abstract on BND-67 was accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place on April 8 - 13, 2022, in New Orleans, Louisiana.
-
Biond Biologics Announces Closing of $15 Million Series C Financing
11/3/2021
Biond Biologics Ltd. announced today the closing of a $15 million, Series C financing round.
-
Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
4/26/2021
Preclinical data demonstrated broad anti-tumor effect of BND-22 through the targeting of ILT2-mediated "do not eat me" signals in macrophages and by activating NK and CD8+ lymphocytes
-
The novel immune checkpoint inhibitor Sanofi deemed worthy of such an investment is BND-22, a humanized IgG4 antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor, an inhibitory receptor expressed on both innate and adaptive immune cells.
-
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
1/12/2021
Biond Biologics Ltd. ("Biond" or the "Company"), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, today announced that it has entered into an exclusive worldwide license agreement with Sanofi (EURONEXT: SAN) (NASDAQ: SNY), for the development and commercialization of BND-22.
-
Biond Biologics Announces Poster Presentations at AACR 2020 Virtual Annual Meeting
7/9/2020
Published work highlights the preclinical development of BND-22, an anti-ILT2 multi-cell checkpoint inhibitor that enhances the anti-tumor activity of innate and adaptive immune cells Also, first publication of a regulatory mechanism of the CD28/B7 immune stimulatory pathway, identifying CD28 shedding as a potential novel target for cancer therapeutics MISGAV, Israel, July 09, 2020 (GLOBE NEWSWIRE) -- Biond Biologics Ltd. (“Biond” or the “Company”), a privately-held biopharmaceuti
-
Biond Biologics Appoints Jerome Zeldis, M.D., Ph.D., Former Chief Medical Officer of Celgene, to Board of Directors and Provides Corporate Update
6/1/2020
Biond Biologics Ltd. (“Biond” or the “Company”), a privately-held biopharmaceutical company, developing novel immunotherapies for cancer and a platform enabling the intracellular delivery of biologics, today announced the appointment of Jerome ("Jerry") Zeldis, M.D., Ph.D. to its Board of Directors.
-
Biond Biologics Announces $17 Million Series B Financing
1/8/2019
Biond was founded in 2016 by the former scientific team of cCam Biotherapeutics, an immuno-oncology company which was fully acquired by Merck in July 2015.
-
MediSapiens to Support Terveystalo With Biobank Data Management and Analytics Solutions
11/15/2018
MediSapiens has partnered with Terveystalo, a leading private healthcare service provider in Finland, to support their biobank operations with scalable, interactive and secure genomic and clinical data solutions.
-
BioRap Technologies To Enter Strategic Collaboration With Pfizer To Research And Develop Novel Immunomodulators
5/31/2016
-
BiondVax Pharmaceuticals Announces Second Quarter 2015 Financial Results And Update
8/24/2015